Ascendis Pharma A/S (NASDAQ:ASND) Given New $225.00 Price Target at The Goldman Sachs Group

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective raised by The Goldman Sachs Group from $200.00 to $225.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 53.08% from the stock’s current price.

A number of other analysts have also recently issued reports on ASND. Cantor Fitzgerald reiterated an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Tuesday. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Oppenheimer decreased their price target on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Finally, JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $167.00 to $168.00 and gave the company an “overweight” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $193.43.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock traded up $20.85 during trading on Thursday, reaching $146.99. The company had a trading volume of 889,965 shares, compared to its average volume of 469,724. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $161.00. The stock’s 50 day moving average price is $131.98 and its two-hundred day moving average price is $132.22. The firm has a market capitalization of $8.92 billion, a price-to-earnings ratio of -18.17 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, research analysts expect that Ascendis Pharma A/S will post -7.12 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds and other institutional investors have recently bought and sold shares of the business. Signaturefd LLC boosted its stake in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the last quarter. Legato Capital Management LLC raised its holdings in Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 134 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth $30,000. Finally, GAMMA Investing LLC grew its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 214 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.